Discuss Cagrilintide on glp1chat
Join the forum to discuss research with other members.
At a glance
Cagrilintide copies the action of amylin, a hormone that helps signal fullness after eating. In clinical studies, researchers measure how this longer-acting signal changes appetite, food intake and body weight.
After a meal, amylin helps tell the brain that enough food has been eaten. Cagrilintide extends that type of message, which is why trials measure fullness, food intake and weight over time. It does not work by directly burning fat. Studies of cagrilintide alone and studies pairing it with a GLP-1 medicine answer different questions.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Weight and metabolic outcomes are central to the cited trials. Findings from cagrilintide alone and from a combination regimen should be read separately.[4][5][12]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Cagrilintide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week/Phase | Weekly Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 36 units | 0.36 mL |
| Weeks 3–4 | 1.2 mg | 72 units | 0.72 mL |
| Weeks 5–6 | 2.4 mg | 144 units | 1.44 mL |
| Weeks 7–16 (Maintenance) | 4.5 mg | 270 units | 2.70 mL |
Route: Subcutaneous injection. Frequency: Once weekly on a consistent day. Note: Doses above 1.0 mL (100 units) require a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) rather than a standard U‑100 insulin syringe. For lower starting doses (≤72 units), a U‑100 insulin syringe provides excellent accuracy.
Additional schedule context & duration
Concise summary of the once‑weekly regimen.
- Goal: Support satiety, reduce food intake, and promote weight management over time[2][4].
- Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate).
- Dose Range: 0.6–4.5 mg weekly with gradual titration every 2 weeks.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for practical volume measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.
Suggested weekly titration approach based on clinical trial designs[1][6].
- Start: 0.6 mg weekly for the first 2 weeks to assess tolerability.
- Escalate: Double the dose every 2 weeks (0.6 → 1.2 → 2.4 → 4.5 mg) as tolerated.
- Target: 4.5 mg weekly by Weeks 7–8; maintain at this dose.
- Frequency: Once per week (subcutaneous) on the same day each week.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or vigorous agitation.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.
Storage Instructions
Proper storage preserves peptide integrity and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[13][14].
- Clean the vial stopper and skin with alcohol; allow to air dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
- Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy[14].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week weekly protocol with gradual titration.
-
Peptide Vials (Cagrilintide, 5 mg each):
- 8 weeks ≈ 4 vials (17.4 mg total)
- 12 weeks ≈ 8 vials (35.4 mg total)
- 16 weeks ≈ 11 vials (53.4 mg total)
-
Syringes:
- Weeks 1–4 (doses ≤72 units): U‑100 insulin syringes work well
- Weeks 5+ (doses >100 units): 3 mL syringes with 25–27G subcutaneous needles
- Per week: 1 syringe
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
The Lancet (2021) — Once‑weekly cagrilintide for weight management: phase 2 dose‑finding trial (Lau et al.) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
Int J Mol Sci (2024) — Amylin, another important neuroendocrine hormone for treatment of diabesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
PMC (2022) — Mediators of amylin action in metabolic control (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
The Lancet (2021) — Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks (opens in a new tab)www.sciencedirect.com
Back to overview ↑ - 06
Research publication
The Lancet (2021) — Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
Brain Res Rev (2005) — Pancreatic amylin as a centrally acting satiating hormone (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PMC (2006) — Pancreatic signals controlling food intake: insulin, glucagon, and amylin (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Research publication
PMC (2016) — Amylin‑mediated control of glycemia, energy balance, and cognition (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
PMC (2024) — Clinical pharmacokinetics of semaglutide: systematic review (includes cagrilintide PK data) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
N Engl J Med (2025) — REDEFINE 2: Cagrilintide–semaglutide in adults with overweight/obesity and type 2 diabetes (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Public health resource
CDC — Vaccine administration: subcutaneous injection technique and site guidance (opens in a new tab)www.cdc.gov
Back to overview ↑ - 14
Public health resource
CDC (PDF) — You Call the Shots: subcutaneous injection diagram and best practices (opens in a new tab)www.cdc.gov
Back to overview ↑ - 15
Research publication
PMC (2019) — Subcutaneous drug delivery: pharmacologic considerations and techniques (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 17
Research publication
The Lancet (2023) — Efficacy and safety of CagriSema in type 2 diabetes: phase 2 trial (Frias et al.) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 18
Research publication
PMC (2024) — Efficacy and safety of cagrilintide and CagriSema: systematic review and meta‑analysis (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.